PDGFRA and glioblastoma: Inhibiting or deleting HIF1α greatly restrains growth advantages exploited by GBM and may disrupt the reciprocal or feedback regulation between PDGFRα-PI3K-AKT and EGFR-ERK pathways once targeting them separately [50].